As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
15 Analysts have issued a Replimune Group, Inc. forecast:
15 Analysts have issued a Replimune Group, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -318 -318 |
39%
39%
|
|
| EBIT (Operating Income) EBIT | -320 -320 |
38%
38%
|
|
| Net Profit | -310 -310 |
45%
45%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
| Head office | United States |
| CEO | Sushil Patel |
| Employees | 331 |
| Founded | 2015 |
| Website | www.replimune.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


